{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:18:38Z","timestamp":1783970318835,"version":"3.55.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infections in infants, older adults, and high-risk populations. The recent approval of new RSV vaccines and monoclonal antibodies marks a turning point in RSV prevention. This review explores these advancements, their immediate and potential long-term effects, and the remaining challenges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Several novel RSV prevention strategies have been approved, including maternal RSVPreF vaccines, infant-targeted monoclonal antibodies like Nirsevimab, and vaccines for older adults. These interventions significantly reduce RSV-related hospitalizations, ICU admissions, and mortality, particularly in high-risk groups. Early evidence also suggests benefits in reducing wheezing during infancy; however, long-term impacts on asthma development remain uncertain. Challenges such as vaccine hesitancy and limited access in low-resource settings remain pressing issues that require sustained focus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>RSV vaccines and monoclonal antibodies are expected to alter clinical management and public health by reducing severe disease burden and RSV transmission. Further research is needed to evaluate their long-term effects, including implications for asthma prevention and pediatric obstructive sleep apnea. Addressing access disparities and public acceptance will be critical for maximizing their global impact.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001455","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:04:20Z","timestamp":1742385860000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Respiratory syncytial virus vaccination: likely and less likely outcomes"],"prefix":"10.1097","volume":"37","author":[{"given":"Dvir","family":"Gatt","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University"},{"name":"Pediatric Pulmonary Unit, Saban Children's Hospital, Soroka University Medical Center, Beer-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Hazan","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University"},{"name":"Pediatric Pulmonary Unit, Saban Children's Hospital, Soroka University Medical Center, Beer-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"R1-20250506","first-page":"e36342","article-title":"Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation","volume":"15","author":"Kaler","year":"2023","journal-title":"Cureus"},{"key":"R2-20250506","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/07487304221081730","article-title":"Effect of the COVID-19 lockdown on asthma biological rhythms","volume":"37","author":"Hazan","year":"2022","journal-title":"J Biol Rhythms"},{"key":"R3-20250506","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacig.2022.06.001","article-title":"Age-dependent rebound in asthma exacerbations after COVID-19 lockdown","volume":"1","author":"Hazan","year":"2022","journal-title":"J Allergy Clin Immunol Glob"},{"key":"R4-20250506","doi-asserted-by":"crossref","first-page":"e1247","DOI":"10.1016\/S2214-109X(20)30303-X","article-title":"RSV lower respiratory tract infection and lung health in the first 2\u200ayears of life","volume":"8","author":"Verwey","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"(2 Suppl)","key":"R5-20250506","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/01.inf.0000053884.21238.13","article-title":"Selected populations at increased risk from respiratory syncytial virus infection","volume":"22","author":"Meissner","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20250506","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.4049\/jimmunol.2101094","article-title":"Age-dependent reduction in asthmatic pathology through reprogramming of postviral inflammatory responses","volume":"208","author":"Hazan","year":"2022","journal-title":"J Immunol"},{"key":"R7-20250506","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1183\/09031936.00040211","article-title":"Preschool asthma after bronchiolitis in infancy","volume":"39","author":"Koponen","year":"2012","journal-title":"Eur Respir J"},{"issue":"(2 Suppl)","key":"R8-20250506","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/01.inf.0000053889.39392.a7","article-title":"Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma","volume":"22","author":"Martinez","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20250506","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1651-2227.2007.00558.x","article-title":"Wheezy babies--wheezy adults? Review on long-term outcome until adulthood after early childhood wheezing","volume":"97","author":"Piippo-Savolainen","year":"2008","journal-title":"Acta Paediatr"},{"key":"R10-20250506","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0140-6736(23)00811-5","article-title":"Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study","volume":"401","author":"Rosas-Salazar","year":"2023","journal-title":"Lancet"},{"key":"R11-20250506","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1164\/rccm.200904-0567ED","article-title":"Causal links between RSV infection and asthma: no clear answers to an old question","volume":"179","author":"Kuehni","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-20250506","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/vaccines12111269","article-title":"The impact of palivizumab for respiratory syncytial virus prophylaxis on preschool childhood asthma","volume":"12","author":"Hasson","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"R13-20250506","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ppul.26817","article-title":"The impact of maternal hyperemesis gravidarum on early childhood respiratory morbidity","volume":"59","author":"Hazan","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"R14-20250506","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00281-020-00781-5","article-title":"Role of viruses in asthma","volume":"42","author":"Jartti","year":"2020","journal-title":"Semin Immunopathol"},{"key":"R15-20250506","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/pathogens12020154","article-title":"Prevention and treatment strategies for respiratory syncytial virus (RSV)","volume":"12","author":"Gatt","year":"2023","journal-title":"Pathogens"},{"key":"R16-20250506","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00006454-199903000-00004","article-title":"Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion","volume":"18","author":"Meissner","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20250506","doi-asserted-by":"crossref","first-page":"513","DOI":"10.23736\/S0026-4946.16.04630-2","article-title":"Prevention of syncytial respiratory virus infection with palivizumab: descriptive and comparative analysis after 12\u200ayears of use","volume":"70","author":"Narbona-Lopez","year":"2018","journal-title":"Minerva Pediatr"},{"key":"R18-20250506","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MOP.0000000000001336","article-title":"Recent advances in the prevention of respiratory syncytial virus in pediatrics","volume":"36","author":"Lipp","year":"2024","journal-title":"Curr Opin Pediatr"},{"key":"R19-20250506","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med"},{"key":"R20-20250506","doi-asserted-by":"crossref","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Jones","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R21-20250506","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40265-022-01829-6","article-title":"Nirsevimab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"R22-20250506","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus Prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"R23-20250506","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV Prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"R24-20250506","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","article-title":"Use of the Pfizer Respiratory Syncytial Virus Vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R25-20250506","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"R26-20250506","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF Vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"R27-20250506","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"(3 Pt 1)","key":"R28-20250506","first-page":"531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"R29-20250506","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","article-title":"Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group","volume":"17","author":"Subramanian","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R30-20250506","doi-asserted-by":"crossref","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R31-20250506","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(19)30721-4","article-title":"Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multicountry case-control study","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"R32-20250506","first-page":"CD015134","article-title":"Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes","volume":"5","author":"Phijffer","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"R33-20250506","doi-asserted-by":"crossref","first-page":"1441786","DOI":"10.3389\/fpubh.2024.1441786","article-title":"The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study","volume":"12","author":"Barbas Del Buey","year":"2024","journal-title":"Front Public Health"},{"key":"R34-20250506","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5\u200ayears in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"R35-20250506","doi-asserted-by":"crossref","first-page":"100379","DOI":"10.1016\/j.jvacx.2023.100379","article-title":"Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: a mathematical modeling study","volume":"15","author":"Willemsen","year":"2023","journal-title":"Vaccine X"},{"key":"R36-20250506","doi-asserted-by":"crossref","first-page":"e47003","DOI":"10.7554\/eLife.47003","article-title":"Reducing respiratory syncytial virus (RSV) hospitalization in a lower-income country by vaccinating mothers-to-be and their households","volume":"9","author":"Brand","year":"2020","journal-title":"Elife"},{"key":"R37-20250506","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"R38-20250506","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/jpc.16197","article-title":"Respiratory syncytial virus, recurrent wheeze and asthma: a narrative review of pathophysiology, prevention and future directions","volume":"58","author":"Binns","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"R39-20250506","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S2213-2600(18)30055-9","article-title":"Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial","volume":"6","author":"Scheltema","year":"2018","journal-title":"Lancet Respir Med"},{"key":"R40-20250506","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1164\/rccm.201609-1812OC","article-title":"Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. six-year follow-up study","volume":"196","author":"Mochizuki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R41-20250506","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S2213-2600(24)00246-7","article-title":"Early-life respiratory syncytial virus disease and long-term respiratory health","volume":"12","author":"Zar","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R42-20250506","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","article-title":"Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries","volume":"41","author":"Getaneh","year":"2023","journal-title":"Vaccine"},{"key":"R43-20250506","doi-asserted-by":"crossref","first-page":"e2576","DOI":"10.1002\/rmv.2576","article-title":"Systematic review of the efficacy and safety of RSV-specific monoclonal antibodies and antivirals in development","volume":"34","author":"Sevendal","year":"2024","journal-title":"Rev Med Virol"},{"key":"R44-20250506","doi-asserted-by":"crossref","first-page":"e29453","DOI":"10.1002\/jmv.29453","article-title":"Respiratory syncytial virus immunoprophylaxis: novel opportunities and a call for equity","volume":"96","author":"Rzymski","year":"2024","journal-title":"J Med Virol"},{"key":"R45-20250506","doi-asserted-by":"crossref","first-page":"e2419229","DOI":"10.1001\/jamanetworkopen.2024.19229","article-title":"Perinatal outcomes after RSV vaccination during pregnancy-addressing emerging concerns","volume":"7","author":"Regan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R46-20250506","doi-asserted-by":"crossref","first-page":"e2419268","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R47-20250506","doi-asserted-by":"crossref","first-page":"e714","DOI":"10.1542\/peds.2012-1672","article-title":"Diagnosis and management of childhood obstructive sleep apnea syndrome","volume":"130","author":"Marcus","year":"2012","journal-title":"Pediatrics"},{"key":"R48-20250506","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ppul.23005","article-title":"Detection of common respiratory viruses in tonsillar tissue of children with obstructive sleep apnea","volume":"50","author":"Yeshuroon-Koffler","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"R49-20250506","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1203\/PDR.0b013e31814257ed","article-title":"Neurotrophins and tonsillar hypertrophy in children with obstructive sleep apnea","volume":"62","author":"Goldbart","year":"2007","journal-title":"Pediatr Res"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T16:00:43Z","timestamp":1746547243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001455","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}